2,6-diphenylbenzaldehyde | 169618-84-2

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-diphenylbenzaldehyde
• 英文别名: [1,1':3',1''-terphenyl]-2'-carbaldehyde
• CAS: 169618-84-2
• 化学式: C₁₉H₁₄O
• 分子量: 258.32
• InChiKey: XVRQHBFFIFIFBS-UHFFFAOYSA-N

物化性质

• 熔点：
  76-77 °C
• 沸点：
  443.5±34.0 °C(Predicted)
• 密度：
  1.114±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,6-diphenylbenzaldehyde 在 dipotassium peroxodisulfate 、 三乙胺-硼烷 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 36.0h， 以79%的产率得到1-phenyl-9H-fluoren-9-one
  参考文献：
  名称：

  Modular Arene Difunctionalization of Unactivated C–O and C–H Bonds by Sequential Chromium-Catalyzed Transformations

  摘要：

  Sequential transformations of unactivated C-O and C-H bonds under chromium catalysis are described. The use of a N-benzyl-substituted imino group as an auxiliary combined with chromium(II) chloride as a precatalyst and 2,3-dichlorobutane as an oxidant allows the arene C-O and C-H bonds to sequentially couple to arylmagnesium reagents to incorporate two identical or different aryl groups into the ortho positions of benzaldehydes.

  DOI：

  10.1021/acs.orglett.9b02504
• 作为产物：
  描述：

  N-[(2,6-diphenyl)benzylidene]-p-toluidine 在 盐酸 作用下， 以 水 为溶剂， 反应 4.0h， 以111 mg的产率得到2,6-diphenylbenzaldehyde
  参考文献：
  名称：

  Catalytic C–H bond arylation of aryl imines and oxazolines in water with ruthenium(II)-acetate catalyst

  摘要：

  Ruthenium(II)-acetate catalyzed C-H bond activation/diarylations of aryl-aldimines, aryl-ketimines and phenyl-oxazolines with aryl bromides in water are reported. Water strongly favours the catalytic diarylation of aryl-ketimines and phenyl-oxazolines with respect to organic solvent. CD (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.03.117

文献信息

• [EN] POLYCYCLIC COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND OR THE COMPOSITION<br/>[FR] COMPOSÉ POLYCYCLIQUE ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE COMPRENANT LE COMPOSÉ POLYCYCLIQUE OU UNE COMPOSITION
  申请人：IDEMITSU KOSAN CO

  公开号：WO2020217229A1

  公开（公告）日：2020-10-29

  Specific polycyclic compounds, a material for an organic electroluminescence device comprising said specific polycyclic compound, an organic electroluminescence device comprising said specific polycyclic compound, an electronic equipment comprising said organic electroluminescence device, a process for preparing said polycyclic compounds, and the use of said polycyclic compounds in an organic electroluminescence. (Formula I) (I)

  特定的多环化合物，一种含有该特定多环化合物的有机电致发光装置材料，一种含有该特定多环化合物的有机电致发光装置，一种包含该有机电致发光装置的电子设备，一种制备所述多环化合物的方法，以及所述多环化合物在有机电致发光中的用途。（公式 I）(I)
• The structure of a one-electron oxidized Mn(<scp>iii</scp>)-bis(phenolate)dipyrrin radical complex and oxidation catalysis control via ligand-centered redox activity
  作者：Laureline Lecarme、Linus Chiang、Jules Moutet、Nicolas Leconte、Christian Philouze、Olivier Jarjayes、Tim Storr、Fabrice Thomas

  DOI：10.1039/c6dt02163h

  日期：——

  The tetradentate ligand dppH3, which features a half-porphyrin and two electron-rich phenol moieties, was prepared and chelated to manganese. The mononuclear Mn(III)-dipyrrophenolate complex 1 was structurally characterized. The metal ion lies in a square pyramidal environment, the apical position being occupied by a methanol molecule. Complex 1 displays two reversible oxidation waves at 0.00 V and

  制备了具有半卟啉和两个富电子酚部分的四齿配体dppH 3，并与锰螯合。Mn（III）-二吡咯酚酸酯单核复合物1的结构特征。金属离子处于方形锥体环境中，其顶端位置被甲醇分子占据。配合物1在0.00 V和0.47 V vs。时显示两个可逆的氧化波。Fc + / Fc，它们被分配给以配体为中心的过程。单电子氧化物质1 +的SbF 6 -结晶，示出八面体的Mn（III）以两个在两个顶端位置协调的水分子居中。键距分析和DFT计算表明，自由基在整个芳族骨架上均离域。复杂1 +的SbF 6 -表现出小号TOT = 3/2自旋状态由于锰（之间的反铁磁耦合III）和配位基团。零个分裂参数d =1.6厘米-1，ê / d = 0.18（1），克⊥ = 1.99和克∥ = 1.98。指示1 2+是整数自旋系统，其分配给与Mn（III）金属中心配位的双氧化配体。既1和1 +的SbF 6 -催化氧化苯乙烯在PhIO
• Regio- and Chemoselective Kumada–Tamao–Corriu Reaction of Aryl Alkyl Ethers Catalyzed by Chromium Under Mild Conditions
  作者：Xuefeng Cong、Huarong Tang、Xiaoming Zeng

  DOI：10.1021/jacs.5b08621

  日期：2015.11.18

  the cross-coupling reactions with aryl ethers via C-O bond activation have attracted broad interest. However, the functionalizations of C-O bonds are mainly limited to nickel catalysis, and selectivity has long been a prominent challenge when several C-O bonds are present in the one molecule. We report here the first chromium-catalyzed selective cross-coupling reactions of aryl ethers with Grignard reagents

  作为一种环境友好的合成工具，通过 CO 键活化与芳基醚的交叉偶联反应引起了广泛的兴趣。然而，CO 键的功能化主要限于镍催化，当一个分子中存在多个 CO 键时，选择性一直是一个突出的挑战。我们在这里报告了第一个铬催化的芳基醚与格氏试剂通过 CO（烷基）键断裂的选择性交叉偶联反应。在室温下使用简单、廉价的铬 (II) 预催化剂结合亚氨基助剂实现了多种转化。它为高效和选择性地构建官能化芳香醛提供了新途径。
• Ruthenium(0)-Catalyzed C–H Arylation of Aromatic Imines under Neutral Conditions: Access to Biaryl Aldehydes
  作者：Feng Hu、Michal Szostak

  DOI：10.1021/acs.orglett.6b01738

  日期：2016.9.2

  The first ruthenium(0)-catalyzed C–H bond arylation of aromatic imines with arylboronates under neutral conditions is reported. This versatile method provides rapid access to a wide range of biaryl aldehydes that are difficult to assemble using traditional methods with high atom economy. A new hydrogen acceptor for Ru(0) arylation has been identified. This atom-economical strategy has potential for

  据报道，在中性条件下，芳族亚胺与芳基硼酸酯的首次钌（0）催化的C–H键芳基化。这种通用的方法可快速访问各种使用芳烃经济性高的传统方法难以组装的联芳基醛。已经确定了Ru（0）芳基化的新氢受体。这种原子经济的策略具有使用可移动的导向基团在Ru（0）催化的C–H键芳基化中直接应用的潜力。据报道，吲哚通过一个顺序的一锅多CH反应进行合成。
• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。